Edesa Biotech, Inc. Quarterly Operating Income (Loss) in USD from Q3 2014 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Edesa Biotech, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q3 2014 to Q4 2024.
  • Edesa Biotech, Inc. Operating Income (Loss) for the quarter ending December 31, 2024 was -$1.9M, a 2.22% decline year-over-year.
  • Edesa Biotech, Inc. Operating Income (Loss) for the twelve months ending December 31, 2024 was -$7.06M, a 18.9% increase year-over-year.
  • Edesa Biotech, Inc. annual Operating Income (Loss) for 2024 was -$7.01M, a 23.9% increase from 2023.
  • Edesa Biotech, Inc. annual Operating Income (Loss) for 2023 was -$9.22M, a 49.8% increase from 2022.
  • Edesa Biotech, Inc. annual Operating Income (Loss) for 2022 was -$18.4M, a 22.4% increase from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2024 -$1.9M -$41.3K -2.22% Dec 31, 2024 10-Q 2025-02-14
Q3 2024 -$1M +$1.37M +57.6% Sep 30, 2024 10-K 2024-12-13
Q2 2024 -$1.93M +$132K +6.38% Jun 30, 2024 10-Q 2024-08-09
Q1 2024 -$2.22M +$190K +7.89% Mar 31, 2024 10-Q 2024-05-10
Q4 2023 -$1.86M +$521K +21.9% Dec 31, 2023 10-Q 2025-02-14
Q3 2023 -$2.37M +$467K +16.5% Sep 30, 2023 10-K 2024-12-13
Q2 2023 -$2.06M +$3.73M +64.4% Jun 30, 2023 10-Q 2024-08-09
Q1 2023 -$2.41M +$2.16M +47.3% Mar 31, 2023 10-Q 2024-05-10
Q4 2022 -$2.38M +$2.78M +53.9% Dec 31, 2022 10-Q 2024-02-09
Q3 2022 -$2.84M +$2.65M +48.3% Sep 30, 2022 10-K 2023-12-15
Q2 2022 -$5.8M +$275K +4.53% Jun 30, 2022 10-Q 2023-08-09
Q1 2022 -$4.58M +$4.94M +51.9% Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$5.16M -$2.55M -97.5% Dec 31, 2021 10-Q 2023-02-10
Q3 2021 -$5.48M -$3.47M -173% Sep 30, 2021 10-K 2022-12-16
Q2 2021 -$6.07M -$4.3M -243% Jun 30, 2021 10-Q 2022-08-12
Q1 2021 -$9.51M -$7.99M -527% Mar 31, 2021 10-Q 2022-05-13
Q4 2020 -$2.61M -$1.51M -136% Dec 31, 2020 10-Q 2022-02-14
Q3 2020 -$2.01M Sep 30, 2020 10-K 2021-12-28
Q2 2020 -$1.77M -$448K -33.9% Jun 30, 2020 10-Q 2021-08-13
Q1 2020 -$1.52M -$975K -180% Mar 31, 2020 10-Q 2021-05-14
Q4 2019 -$1.11M -$700K -173% Dec 31, 2019 10-Q 2021-02-16
Q2 2019 -$1.32M -$898K -213% Jun 30, 2019 10-Q 2020-08-12
Q1 2019 -$541K +$803K +59.8% Mar 31, 2019 10-Q 2020-05-15
Q4 2018 -$406K +$984K +70.8% Dec 31, 2018 10-Q 2020-02-13
Q2 2018 -$422K +$872K +67.4% Jun 30, 2018 10-Q 2019-08-14
Q1 2018 -$1.34M -$196K -17.1% Mar 31, 2018 10-Q 2019-05-08
Q4 2017 -$1.39M +$24.6K +1.74% Dec 31, 2017 10-Q 2019-02-05
Q3 2017 -$1.37M -$52.3K -3.97% Sep 30, 2017 10-K 2018-11-30
Q2 2017 -$1.29M -$105K -8.85% Jun 30, 2017 10-Q 2018-08-08
Q1 2017 -$1.15M -$51.6K -4.71% Mar 31, 2017 10-Q 2018-05-07
Q4 2016 -$1.41M -$107K -8.19% Dec 31, 2016 10-Q 2018-02-07
Q3 2016 -$1.32M Sep 30, 2016 10-K 2017-12-01
Q2 2016 -$1.19M Jun 30, 2016 10-Q 2017-08-09
Q1 2016 -$1.1M Mar 31, 2016 10-Q 2017-05-09
Q4 2015 -$1.31M Dec 31, 2015 10-Q 2017-02-06
Q3 2014 -$452K Sep 30, 2014 10-K 2016-12-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.